Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AARD NASDAQ:ALVR NASDAQ:PMN NASDAQ:QTTB On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAARDAardvark Therapeutics$4.34+3.3%$4.78$3.35▼$17.94$94.70M5.11243,581 shs12,882 shsALVRAlloVir$5.21+5.9%$5.90$7.96▼$24.15$49.48M0.6315,685 shs156,115 shsPMNPromis Neurosciences$10.59+2.2%$12.48$6.27▼$39.75$94.95M-0.229,875 shs33,833 shsQTTBQ32 Bio$12.83+81.0%$6.03$1.35▼$12.51$217.60M-0.05311,945 shs8.00 million shsTen Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAARDAardvark Therapeutics-7.49%-3.89%-22.08%-66.07%-60.00%ALVRAlloVir0.00%+3.80%-19.48%-55.15%+76.34%PMNPromis Neurosciences-5.65%-2.72%-7.83%-47.83%-17.94%QTTBQ32 Bio+22.24%+16.80%+13.99%+49.89%+337.65%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAARDAardvark Therapeutics$4.34+3.3%$4.78$3.35▼$17.94$94.70M5.11243,581 shs12,882 shsALVRAlloVir$5.21+5.9%$5.90$7.96▼$24.15$49.48M0.6315,685 shs156,115 shsPMNPromis Neurosciences$10.59+2.2%$12.48$6.27▼$39.75$94.95M-0.229,875 shs33,833 shsQTTBQ32 Bio$12.83+81.0%$6.03$1.35▼$12.51$217.60M-0.05311,945 shs8.00 million shsTen Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAARDAardvark Therapeutics-7.49%-3.89%-22.08%-66.07%-60.00%ALVRAlloVir0.00%+3.80%-19.48%-55.15%+76.34%PMNPromis Neurosciences-5.65%-2.72%-7.83%-47.83%-17.94%QTTBQ32 Bio+22.24%+16.80%+13.99%+49.89%+337.65%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAARDAardvark Therapeutics 2.46Hold$19.70353.92% UpsideALVRAlloVir 0.00N/AN/AN/APMNPromis Neurosciences 2.75Moderate Buy$26.50150.35% UpsideQTTBQ32 Bio 2.60Moderate Buy$13.505.20% UpsideCurrent Analyst Ratings BreakdownLatest ALVR, AARD, PMN, and QTTB Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/22/2026QTTBQ32 Bio MizuhoSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$14.005/22/2026QTTBQ32 Bio MizuhoSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$14.005/20/2026PMNPromis NeurosciencesBrookline Capital MarketsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy5/18/2026QTTBQ32 Bio Cantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight5/18/2026QTTBQ32 Bio Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold5/15/2026AARDAardvark Therapeutics B. Riley FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$8.00 ➝ $7.005/15/2026AARDAardvark Therapeutics BTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Hold5/15/2026AARDAardvark Therapeutics Morgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingEqual Weight ➝ Underweight$7.00 ➝ $3.005/13/2026AARDAardvark Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)5/11/2026QTTBQ32 Bio Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (D+) ➝ Hold (C-)5/5/2026QTTBQ32 Bio HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$13.00(Data available from 5/27/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAARDAardvark TherapeuticsN/AN/AN/AN/A$3.99 per shareN/AALVRAlloVirN/AN/AN/AN/A$29.35 per shareN/APMNPromis NeurosciencesN/AN/AN/AN/A$6.77 per shareN/AQTTBQ32 Bio$53.74M4.05$3.35 per share3.83$2.73 per share4.70Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAARDAardvark Therapeutics-$57.59M-$3.21N/AN/AN/AN/A-61.71%-56.29%N/AALVRAlloVir-$190.42M-$20.23N/AN/AN/AN/A-71.03%-61.27%N/APMNPromis Neurosciences-$39.72M-$14.51N/AN/AN/AN/A-237.99%-151.04%8/12/2026 (Estimated)QTTBQ32 Bio$29.82M$2.664.82N/AN/AN/A149.23%34.50%8/5/2026 (Estimated)Latest ALVR, AARD, PMN, and QTTB EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/12/2026Q1 2026PMNPromis Neurosciences-$1.06-$1.26-$0.20-$1.26N/AN/A5/7/2026Q1 2026AARDAardvark TherapeuticsN/A-$0.99N/A-$0.99N/AN/A5/5/2026Q1 2026QTTBQ32 Bio-$0.68-$0.54+$0.14-$0.54$39.74 millionN/A3/23/2026Q4 2025AARDAardvark Therapeutics-$0.81-$0.81N/A-$0.81N/AN/A3/10/2026Q4 2025QTTBQ32 Bio-$1.06$3.65+$4.71$4.58N/A$53.74 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthAARDAardvark TherapeuticsN/AN/AN/AN/AN/AALVRAlloVirN/AN/AN/AN/AN/APMNPromis NeurosciencesN/AN/AN/AN/AN/AQTTBQ32 BioN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAARDAardvark TherapeuticsN/A8.068.06ALVRAlloVirN/A86.7886.78PMNPromis NeurosciencesN/A9.929.92QTTBQ32 Bio0.045.365.36Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAARDAardvark TherapeuticsN/AALVRAlloVir66.05%PMNPromis Neurosciences50.13%QTTBQ32 Bio31.32%Insider OwnershipCompanyInsider OwnershipAARDAardvark TherapeuticsN/AALVRAlloVir32.07%PMNPromis Neurosciences1.50%QTTBQ32 Bio40.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAARDAardvark Therapeutics1821.82 millionN/AN/AALVRAlloVir1105.04 million3.43 millionNo DataPMNPromis Neurosciences58.97 million8.83 millionNot OptionableQTTBQ32 Bio3916.96 million10.17 millionN/AALVR, AARD, PMN, and QTTB HeadlinesRecent News About These CompaniesQ32 Bio announces $55M private placement3 minutes ago | seekingalpha.comQ32 Bio Announces $55 Million Private Placement Financing2 hours ago | prnewswire.comWall Street Analysts Think Q32 Bio (QTTB) Could Surge 145.69%: Read This Before Placing a BetMay 26 at 10:56 AM | zacks.comMizuho initiates coverage of Q32 Bio (QTTB) with outperform recommendationMay 23, 2026 | msn.comQ32 Bio Inc. Common Stock (QTTB) Short InterestMay 22, 2026 | nasdaq.comCantor Fitzgerald initiates coverage of Q32 Bio (QTTB) with overweight recommendationMay 19, 2026 | msn.comQ32 Bio (QTTB) price target increased by 15.12% to 16.83May 14, 2026 | msn.comWall Street Analysts Believe Q32 Bio (QTTB) Could Rally 163.42%: Here's is How to TradeMay 8, 2026 | zacks.comHC Wainwright Has Optimistic Outlook of Q32 Bio Q2 EarningsMay 7, 2026 | marketbeat.comFY2029 Earnings Forecast for Q32 Bio Issued By HC WainwrightMay 6, 2026 | marketbeat.comRegulatory Compliance Risks: Q32 Bio Warns of Internal Control Challenges Under Sarbanes-Oxley and Potential Impact on InvestorsMay 6, 2026 | tipranks.comQ32 Bio's (QTTB) Buy Rating Reaffirmed at HC WainwrightMay 5, 2026 | marketbeat.comQ32 Bio (NASDAQ:QTTB) Announces Earnings Results, Beats Estimates By $0.14 EPSMay 5, 2026 | marketbeat.comQ32 Bio Reports First Quarter 2026 Financial Results and Provides Corporate UpdateMay 5, 2026 | prnewswire.comQ32 Bio (QTTB) Expected to Announce Quarterly Earnings on ThursdayApril 30, 2026 | marketbeat.comQ32 Bio (NASDAQ:QTTB) Trading Down 3.8% - What's Next?April 30, 2026 | marketbeat.comQ32 Bio Expands ATM Offering With New $75M ProspectusApril 24, 2026 | tipranks.comQ32 Bio Inc. Common Stock (QTTB) Insider ActivityApril 18, 2026 | nasdaq.comQ32 Bio to Participate in the 25th Annual Needham Virtual Healthcare ConferenceApril 8, 2026 | prnewswire.comDoes Q32 Bio (QTTB) Have the Potential to Rally 97.66% as Wall Street Analysts Expect?March 30, 2026 | zacks.comQ32 Bio: Bempikibart Keeps The Alopecia Areata Bull Case AliveMarch 30, 2026 | seekingalpha.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeALVR, AARD, PMN, and QTTB Company DescriptionsAardvark Therapeutics NASDAQ:AARD$4.32 +0.12 (+2.86%) As of 10:00 AM Eastern This is a fair market value price provided by Massive. Learn more.Aardvark Therapeutics, Inc. operates as a biotechnology company. It engages in the development of a novel small molecule therapeutics for obesity and metabolic diseases. The company was founded by Tien Lee in 2017 and is headquartered in San Diego, CA.AlloVir NASDAQ:ALVR$5.21 +0.29 (+5.89%) As of 05/26/2026AlloVir, Inc. engages in the research, development and commercialization of off-the-shelf VST therapies to prevent and treat severe viral-associated diseases. It develops novel cell therapies with a focus on restoring natural immunity against life-threatening virus-associated diseases in patients with severely weakened immune systems. The firm's technology platforms deliver commercially scalable solutions by leveraging off-the-shelf, allogeneic, multi-virus specific T-cells targeting devastating viral pathogens for immunocompromised patients under viral attack. The company was founded by Malcolm K. Brenner, Juan F. Vera, Helen E. Heslop, Cliona M. Rooney, John R. Wilson, and Ann M. Leen in August 2013 and is headquartered in Waltham, MA.Promis Neurosciences NASDAQ:PMN$10.58 +0.23 (+2.17%) As of 09:48 AM Eastern This is a fair market value price provided by Massive. Learn more.ProMIS Neurosciences, Inc. discovers and develops antibody therapies and therapeutic vaccines neurodegenerative diseases and other misfolded protein diseases in Canada. The company's proprietary discovery platform comprises ProMIS and Collective Coordinates algorithms to predict novel targets known as disease specific epitopes on the molecular surface of misfolded proteins. Its lead product candidates comprise of PMN310, a monoclonal antibody (mAb) for toxic oligomers in AD; PMN267, a TDP-43; and PMN442, a mAb targeting toxic a-syn oligomers and seeding fibrils. The company was formerly known as Amorfix Life Sciences Ltd. and changed its name to ProMIS Neurosciences, Inc. in July 2015. ProMIS Neurosciences, Inc. was incorporated in 2004 and is headquartered in Toronto, Canada.Q32 Bio NASDAQ:QTTB$12.54 +5.46 (+76.94%) As of 10:01 AM Eastern This is a fair market value price provided by Massive. Learn more.Q32 Bio Inc., a clinical-stage biotechnology company, develops biologic therapeutics to restore healthy immune balance in patients with autoimmune and inflammatory diseases driven by pathological immune dysfunction in the United States. Its lead product candidate is ADX-097, a humanized anti-C3d monoclonal antibody fusion protein to restore complement regulation, which has completed Phase I clinical trial for the treatment of renal and other complement-mediated diseases of high unmet need, including lupus nephritis, immunoglobulin A nephropathy, complement component 3 glomerulopathy, and anti-neutrophil cytoplasmic antibody-associated vasculitis. The company is also developing Bempikibart (ADX-914), a fully human antiinterleukin-7 receptor alpha antagonist monoclonal antibody designed to re-regulate adaptive immune function by blocking signaling mediated by interleukin-7 and thymic stromal lymphopoietin that is Phase II clinical trial for the treatment of atopic dermatitis and alopecia areata. Q32 Bio Inc. was formerly known as AdMIRx Inc. and changed its name to Q32 Bio Inc. in April 2020. The company was founded in 2017 and is based in Waltham, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas AutoZone's Pullback Sets Up a Long-Term Buying Opportunity AST SpaceMobile’s June Launch Plan Puts Its 2026 Satellite Goal Back in Focus Powerhouse Williams-Sonoma Heading to Fresh Highs in 2026 Quantum Stocks Just Got a Lifeline—Who Benefits Most? Why BJ’s Wholesale Club Stock Could Be Ready for a Rebound 5 High-Yield Stocks and ETFs to Buy and Hold for the Next Decade Rocket Companies Turns Around, But Mortgage Risk Remains After NVIDIA, Broadcom's Earnings Are Next—Here's What to Watch Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
